There are currently 27 active clinical trials seeking participants for Idiopathic Pulmonary Fibrosis research studies. The states with the highest number of trials for Idiopathic Pulmonary Fibrosis participants are California, Florida, Texas and Pennsylvania.
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
Recruiting
Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years. Objective: To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis. Eligibility: People aged 18 years and older with interstitial lung disease... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/09/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Recruiting
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +371 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
Recruiting
Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Snyder Building 480 Ray C. Hunt Drive, Charlottesville, Virginia
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: GSK Investigational Site, Los Angeles, California +59 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
Recruiting
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/23/2025
Locations: Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research, Miami, Florida
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/17/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +502 locations
Conditions: Idiopathic Pulmonary Fibrosis
NAL ER IPF Respiratory Function and Safety Study
Recruiting
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Mayo Clinic, Rochester, Minnesota +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has com... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +113 locations
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Recruiting
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +179 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/03/2025
Locations: WISPer site in Newport Beach, CA, Newport Beach, California +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Recruiting
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/14/2025
Locations: University of California San Francisco, San Francisco, California +15 locations
Conditions: Idiopathic Pulmonary Fibrosis